| Sanofi–Lonza: rec protein production, 201703– collab 50/50 jv to establish biologics production facility in CH w initial investment of CHF290 (€270m) |
2017-02-27 |
| Adaptimmune–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| Galenica–Ally Bridge Group: investment, 201702 investment €na by ABG |
2017-02-23 |
| Nabriva–Ally Bridge Group: investment, 201702 investment €na by ABG |
2017-02-23 |
| Tesaro–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| WuXi PharmaTech–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| Neovacs–ActeaVentures: business consulting, 201702 supply service business development advisor for Neovacs license deal w BioSense Global LLC |
2017-02-21 |
| Bayer–Yara: digital farming, 201702– collab + license ww to ImageIT mobile imaging technology for plant monitoring + farming recommendations |
2017-02-20 |
| Oncgnostics–Thuringia (govt): investment, 201702 additional investment of €500k from bm|t |
2017-02-20 |
| BioMedPartners–SEVERAL: investment, 201702 first closing CHF75m of BioMedInvest III fund incl cornerstone investor EIF + Berner Kantonalbank |
2017-02-16 |
| Selecta Biosciences–Lonza: gene therapy products, 201702– supply contract manufacturing of Anc80-AAV-based gene therapy product by Lonza Houston Inc |
2017-02-16 |
| Boehringer–Cornell Univ: drug discovery, 201702– collab 3y identify COPD treatm approaches Weill Cornell Medicine Dept of Genetic Medicine |
2017-02-15 |
| Boehringer–Inventiva: pharmaceutical, 201702 collab r+d existent |
2017-02-15 |
| Jecure Therapeutics–Versant Ventures: investment, 201702 financing round Series A $20m from founding investor Versant Ventures |
2017-02-15 |
| Immunicum–MacDougall Biomedical Communications: public relations, 201702 service existent by MacDougall |
2017-02-13 |
| Santhera–SEVERAL: credit, 201702–202202 senior unsecured convertible bonds CHF60m 5% due 202202 |
2017-02-10 |
| Evotec–Novo Group: investment, 201702 strategic investment of €90.3m 13.15m new Evotec shares at €6.87/share resulting in 8.9% ownership by Novo A/S |
2017-02-09 |
| NewLink Genetics–Cevec: rec protein production technology, 201702– license €na to CAP GT + CAP Go cell lines for Zika vaccine developm + commerc |
2017-02-09 |
| Albany Molecular–Bruker: mass spectrometer, 201702 supply MALDI PharmaPulse system to AMRI by Bruker Daltonics + HighRes Biosolutions |
2017-02-07 |
| Atriva Therapeutics–High-Tech Gründerfonds: investment, 201702 seed financing round led by Stichting Participatie Atriva + HTGF |
2017-02-07 |
| Atriva Therapeutics–SEVERAL: investment, 201702 seed financing round led by Stichting Participatie Atriva + HTGF plus private investors |
2017-02-07 |
| Atriva Therapeutics–Stichting Participatie Atriva: investment, 201702 seed financing round led by SPA + HTGF |
2017-02-07 |
| Bruker–Albany Molecular: mass spectrometry, 201702– collab developm of HTS applications using MALDI PharmaPulse system from Bruker + HighRes |
2017-02-07 |
| Labor Limbach–Numares: NMR-based IVD tests, 201702 collab existent Labor Limbach offers IVD test LipoComplete |
2017-02-07 |
| Prexton Therapeutics–Forbion: investment, 201702 financing round Series B totalling €29m co-led by new investors Forbion + Seroba |
2017-02-07 |
| Prexton Therapeutics–Merck (DE): investment, 201702 financing round Series B totalling €29m incl returning co-investor Merck Ventures |
2017-02-07 |
| Prexton Therapeutics–Seroba: investment, 201702 financing round Series B totalling €29m co-led by new investors Forbion + Seroba |
2017-02-07 |
| Prexton Therapeutics–SEVERAL: investment, 201702 financing round Series B €29m co-led by new investors Forbion + Seroba |
2017-02-07 |
| Prexton Therapeutics–Sunstone Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Sunstone Capital |
2017-02-07 |
| Prexton Therapeutics–Ysios Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Ysios Capital |
2017-02-07 |
| GSK–Bruker: mass spectrometer, 201702 supply existent MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System at GSK Platform Tech + Science group |
2017-02-06 |
| Wilex–Hopp Group: investment, 201702– financing commitment of up to €10m by Dievini Hopp [not announced whether credit or investment] |
2017-02-06 |
| Coral BioNet–UV-Cap: investment, 201702 acquisition 100% of Scil Proteins GmbH from Bionet Ventures GmbH by UV-Cap GmbH & Co KG |
2017-02-03 |
| Leukocare–Rentschler: investment, 201702 acquisition of 10% stake in Leukocare AG by Rentschler Biotechnologie GmbH as part of strategic alliance |
2017-02-02 |
| Ottobock–Steeper: prosthetic, 201702 acquisition of BeBionic hand product range by Ottobock from Steeper |
2017-02-02 |
| Rentschler–Leukocare: drug formulation technology, 201702– collab strategic alliance using SPS technology for biopharmaceuticals |
2017-02-02 |
| Immunic–Saxony-Anhalt (govt): investment, 201702 investment Series A €4m by new investor IBG bringing total to €21.7m |
2017-02-01 |
| Lonza–SEVERAL: investment, 201701–201702 capital increase CHF865m placing 5m new shares at CHF173/share to selected/qualified investors |
2017-01-31 |
| Regeneron–Indivumed: tissue banking, 201701– collab + supply €na tissue samples w clinical + molecular data for cancer research |
2017-01-31 |
| Medizinsches Labor Bremen–Sonic Healthcare: investment, 201701– acquisition for €63m (cash + debt free) of MLB by Sonic Healthcare Ltd |
2017-01-30 |
| ProteomeTools project–BioNTech: proteomics, 201701 collab existent JPM Peptide Technologies is project partner |
2017-01-30 |
| ProteomeTools project–SAP: proteomics, 201701 collab existent SAP is project partner |
2017-01-30 |
| ProteomeTools project–Thermo Fisher: proteomics, 201701 collab existent Thermo Fisher Scientific is project partner |
2017-01-30 |
| ProteomeTools project–TU Munich: proteomics, 201701 collab existent TUM is coordinating project partner in developing PROPEL library |
2017-01-30 |
| SGS–SEVERAL: credit, 201701–202601 nine year CHF375m straight bond with coupon of 0.55% |
2017-01-30 |
| Sonic Healthcare–McDermott Will & Emery: legal services, 201701 advisor for acquisition of Medical Lab Bremen by Sonic Healthcare Ltd |
2017-01-30 |
| United Kingdom (govt)–Qiagen: genomic database, 201701– Genomics England to use HGMD Online Professsional solution for 100,000 Genomes Project |
2017-01-30 |
| Actelion–JnJ: investment, 201701–201706 acquisition $30b all-cash tender offer funded w JnJ cash held outside of US |
2017-01-26 |
| Cellestia Biotech–PPF Group: investment, 201701 seed financing round Series C totalling CHF5.2m incl Sotio/PPF Group + private investors |
2017-01-26 |
| Actelion–Enamine: chemical compound library, 201701– collab expansion supply of screening compound library to Actelion |
2017-01-23 |
| Merck (DE)–Domain Therapeutics: cancer drugs, 201701– collab developm + ww license to adenosine receptor antagonists |
2017-01-23 |
| Affimed–SEVERAL: investment, 201701 public offering $18m + $2.7m with 10m+1.5m common shares at $1.8/share |
2017-01-19 |
| Asahi Kasei–Evotec: drug discovery, 201701– supply service €na expansion into integrated drug discovery collab for inhibitors of ion channel targets |
2017-01-19 |
| Fibrocor Therapeutics–Evotec: drug discovery services, 201701– collab developm fibrosis drugs w all drug discovery activities done by Evotec |
2017-01-17 |
| Fibrocor Therapeutics–Evotec: investment, 201701 Evotec to receive equity stake in Fibrocor as part of collaboration |
2017-01-17 |
| Fibrocor Therapeutics–SEVERAL: investment, 201701 seed financing C$2.8m ($2.1m) incl cash from co-founder MaRS Innovation |
2017-01-17 |
| Mologen–SEVERAL: credit, 201701–202501 convertible bonds €4.99m at 6% incl major shareholder GTD |
2017-01-17 |
| Northwell Health–Indivumed: tissue bank, 201701– collab to create cancer research biobank |
2017-01-17 |
| Luxendo–Huntsworth: public relations, 201701 service existent by Citigate Dewe Rogerson |
2017-01-12 |
| Luxendo–SEVERAL: investment, 201701 financing round Series A extension €2m bringing total to €8m co-led by LSP + EMBL Ventures + EMBLEM |
2017-01-12 |
| Merck (DE)–Palantir: data integration and analysis s/w, 201701– collab €na use initially in healthcare ultimately in all 3 business sectors of Merck |
2017-01-12 |
| Crescendo Biologics–Genedata: bioinformatics, 201701– license to Genedata Biologics as workflow platform for internal + partnered Humabody programs |
2017-01-10 |
| Amgen–Immatics: cancer immunotherapy, 201701– strategic collab $30m upfront + $500m milestones + royalties combining Xpresident + BiTE technologies |
2017-01-09 |
| Arrowhead–Silence Therapeutics: investment, 201701 acquisition 6.83m common shares = 9.21% shareholding for $11.3m |
2017-01-09 |
| Epidarex Capital–Lilly: investment, 201701 existent one of several investors in Epidarex is Eli Lilly |
2017-01-09 |
| Eternygen–Berlin (govt): investment, 201701 financing round Series A totalling €8m incl co-investor VC Fonds Technologie managed by IBB |
2017-01-09 |
| Eternygen–Epidarex Capital: investment, 201701 financing round Series A totalling €8m incl lead investor Epidarex Capital |
2017-01-09 |
| Eternygen–Evotec: investment, 201701 financing round Series A totalling €8m incl co-investor Evotec AG |
2017-01-09 |
| Eternygen–MC Services: public relations, 201701 service existent by MC Services AG |
2017-01-09 |
| Eternygen–SEVERAL: investment, 201701 financing round Series A €8m led by Epidarex Capital plus Evotec + VC Fonds Technologie + 2 family offices et al |
2017-01-09 |
| Merck (DE)–Univ Texas: oncology, 201701–201912 strategic collab using MD Anderson’s APOLLO platform for cancer drug development |
2017-01-09 |
| OmicSoft–Qiagen: investment, 201701 acquisition €na of OmicSoft by Qiagen |
2017-01-09 |
| Servier–McDermott Will & Emery: legal services, 201701 advisor immuno-oncology co-developm agreem of Servier with Pieris Pharmaceuticals |
2017-01-09 |
| Anokion–Celgene: investment, 201701 acquisition of equity interest by Celgene as part of research collab research plus excl option to acquire Anokion |
2017-01-08 |
| Celgene–Anokion: immune tolerance inducing drugs, 201701– collab research $45m upfront + $10m milestones + equity share + right to acquire Anokion |
2017-01-08 |
| HepaRegenix–Boehringer: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion |
2017-01-05 |
| HepaRegenix–Germany (govt): investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion |
2017-01-05 |
| HepaRegenix–High-Tech Gründerfonds: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion |
2017-01-05 |
| HepaRegenix–MC Services: public relations, 201701 service existent by MC Services AG |
2017-01-05 |
| HepaRegenix–Novo Group: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion |
2017-01-05 |
| HepaRegenix–SEVERAL: investment, 201701 financing round Series A €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion |
2017-01-05 |
| Merck (US)–Valneva: cell line, 201701– research license €na for development of new vaccines using EB66 technology to MSD Animal Health |
2017-01-05 |
| Servier–Pieris: cancer immunotherapy, 201701– collab €30m upfront + milestones to develop bi-specific ABs using Anticalin technology incl PRS-322 |
2017-01-05 |
| Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners |
2017-01-05 |
| Affimed–Univ Texas: cancer immunotherapy, 201701– collab clinical + commerc to evalaute TandAbs with natural killer cell product of MD Anderson |
2017-01-04 |
| Aptarion Biotech–Noxxon: investment, 201701 Noxxon receives Aptarion shares as part of transfer of preclinical assets to Aptarion |
2017-01-04 |
| Aptarion Biotech–Noxxon: Spiegelmer technology, 201701 acquisition techn + preclinical assets + lab assets from Noxxon for cash + royalties + shares |
2017-01-04 |
| BioControl Systems–Merck (DE): investment, 201701 acquisition €na of BioControl Systems Inc by Merck KGaA |
2017-01-04 |
| InVivo Biotech Services–Bruker: investment, 201701 acquisition €na of InVivo Biotech Services GmbH by Bruker |
2017-01-04 |
| SCiLS GmbH–Bruker: investment, 201701 acquisition €na of SCiLS GmbH by Bruker |
2017-01-04 |
| Tiziana–Novimmune: therapeutic antibody, 201701– license excl €na to develop + commercialise anti-IL-6R MAb NI-1201 |
2017-01-04 |
| Laboratoire LCA (MA)–SGS: investment, 201701 acqisition by SGS |
2017-01-03 |
| Bio-ITech–Eppendorf: investment, 2017Q1 acquisition of majority share in Bio-ITech BV by Eppendorf |
2017-01-01 |
| Cutiss–Univ Zurich: investment, 2017 seed funding from UZH Life Sciences Fund |
2017-01-01 |
| dKK GmbH–Bavaria (govt): science/business park services, 201704– supply serivce dKK GmbH Martinried is new tenant at IZB Martinsried |
2017-01-01 |
| Horizon Discovery–ERS Genomics: CRISPR technology, 201701– license ww non-excl expansion |
2017-01-01 |
| Immunic–Bavaria (govt): science/business park services, 201701– supply service Immunic AG is new tenant at IZB Martinsried |
2017-01-01 |
| Inveox–SEVERAL: investment, 2017 seed financing round €1m from four business angels |
2017-01-01 |
| Middle Peak Medical–Symetis: investment, before 2017 acquisition by Symetis SA |
2017-01-01 |
| Pionyr Immunotherapeutics–Minapharm: biopharma production, 2017– supply service cell line + process dev + production of therap antibody by ProBioGen |
2017-01-01 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 23 24 25 ... 30 31 32 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
